Where can I find the actual Q1 2017 financial results?

The actual financial and operating results for the first quarter ended March 31, 2017, are detailed in the press release furnished as Exhibit 99.1 to this 8-K filing. Investors should consult this press release for specific figures.

What is the significance of this 8-K filing for Regeneron investors?

This 8-K filing is important as it officially releases Regeneron's Q1 2017 earnings report to the public via a furnished press release. It marks the official disclosure of the company's performance for the period and provides key financial and operational data.

Does the information in this filing carry the same liability as a standard SEC filing?

No, the company explicitly states that the information included or incorporated in Item 2.02, including Exhibit 99.1, shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in other filings unless expressly stated. This means it carries different legal implications than information formally filed.

REGN 8-K: Earnings & Results

Summary

Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on May 4, 2017, to report its financial and operating results for the first quarter ended March 31, 2017. This filing primarily serves to furnish the associated press release (Exhibit 99.1) to the SEC, which contains the detailed results. Investors should refer to this press release for specific performance metrics, revenue figures, and business updates for the period. The company emphasizes that the information furnished is not deemed 'filed' under Section 18 of the Exchange Act, nor incorporated by reference into other SEC filings unless specifically stated.

Key Highlights

1Regeneron announced its Q1 2017 financial and operating results via a press release furnished with this 8-K.
2The press release (Exhibit 99.1) is the primary source of detailed Q1 2017 financial and operational information for investors.
3The filing date is May 4, 2017, with the event date listed as May 3, 2017, indicating the release of results occurred around this time.
4This 8-K is a procedural filing, providing access to the company's quarterly performance update.
5Information furnished in this filing is subject to specific disclaimers regarding its 'filed' status under SEC regulations.

REGENERON PHARMACEUTICALS, INC. 8-K Report, Financial Results (May 4, 2017)

Summary

Key Highlights

Frequently Asked Questions